Verrica Pharmaceuticals Inc. Research and Development Expense
Verrica Pharmaceuticals Inc. (VRCA) reported Research and Development Expense of $6.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. research and development expense for the quarter ending 2026-06-30 was $6.03M, a 226.87% increase year-over-year.
- Verrica Pharmaceuticals Inc. research and development expense for the quarter ending 2026-03-31 was $3.86M, a 69.00% increase year-over-year.
- Verrica Pharmaceuticals Inc. research and development expense for the quarter ending 2025-12-31 was $2.52M, a 115.75% increase year-over-year.
- Verrica Pharmaceuticals Inc. research and development expense for the quarter ending 2025-09-30 was $2.21M, a 8.32% decline year-over-year.
- Verrica Pharmaceuticals Inc. research and development expense for fiscal 2025 was $8.86M, a 25.21% decline from fiscal 2024.
- Verrica Pharmaceuticals Inc. research and development expense for fiscal 2024 was $11.84M, a 41.66% decline from fiscal 2023.
- Verrica Pharmaceuticals Inc. research and development expense for fiscal 2023 was $20.30M, a 66.38% increase from fiscal 2022.
- Verrica Pharmaceuticals Inc. research and development expense for fiscal 2022 was $12.20M, a 23.42% decline from fiscal 2021.
| Period end | Research and Development Expense | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.03M 10-Q · filed 2026-08-06 | $9.89M 10-Q · filed 2026-08-06 | $12.41M derived: sum of 3 quarters · filed 2026-08-06 | $14.62M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $3.86M 10-Q · filed 2026-05-12 | $6.38M derived: sum of 2 quarters · filed 2026-05-12 | $8.59M derived: sum of 3 quarters · filed 2026-05-12 | $10.43M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $4.72M derived: sum of 2 quarters · filed 2026-03-11 | $6.57M derived: sum of 3 quarters · filed 2026-08-06 | $8.86M 10-K · filed 2026-03-11 | ||||
| 2025-09-30 | $2.21M 10-Q · filed 2025-11-14 | $4.05M derived: sum of 2 quarters · filed 2026-08-06 | $6.33M 10-Q · filed 2025-11-14 | $7.50M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $1.85M 10-Q · filed 2026-08-06 | $4.13M 10-Q · filed 2026-08-06 | $5.30M derived: sum of 3 quarters · filed 2026-08-06 | $7.70M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $2.28M 10-Q · filed 2026-05-12 | $3.45M derived: sum of 2 quarters · filed 2026-05-12 | $5.86M derived: sum of 3 quarters · filed 2026-05-12 | $9.18M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.57M derived: sum of 2 quarters · filed 2026-03-11 | $6.89M derived: sum of 3 quarters · filed 2026-03-11 | $11.84M 10-K · filed 2026-03-11 | ||||
| 2024-09-30 | $2.40M 10-Q · filed 2025-11-14 | $5.72M derived: sum of 2 quarters · filed 2025-11-14 | $10.67M 10-Q · filed 2025-11-14 | $10.67M 10-Q · filed 2024-11-05 | $15.99M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $3.32M 10-Q · filed 2025-08-12 | $8.27M 10-Q · filed 2025-08-12 | $13.59M derived: sum of 3 quarters · filed 2025-08-12 | $20.10M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $4.95M 10-Q · filed 2025-05-13 | $10.27M derived: sum of 2 quarters · filed 2025-05-13 | $16.78M derived: sum of 3 quarters · filed 2025-05-13 | $22.50M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $5.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $11.83M derived: sum of 2 quarters · filed 2025-03-11 | $17.55M derived: sum of 3 quarters · filed 2025-03-11 | $20.30M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $6.51M 10-Q · filed 2024-11-05 | $12.23M derived: sum of 2 quarters · filed 2024-11-05 | $14.97M 10-Q · filed 2024-11-05 | $18.00M derived: sum of 4 quarters · filed 2024-11-05 | ||||
| 2023-07-21 | $4.50M 10-K · filed 2026-03-11 | |||||||
| 2023-06-30 | $5.72M 10-Q · filed 2024-08-14 | $8.46M 10-Q · filed 2024-08-14 | $11.49M derived: sum of 3 quarters · filed 2024-08-14 | $14.27M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $2.74M 10-Q · filed 2024-05-13 | $5.77M derived: sum of 2 quarters · filed 2024-05-13 | $8.55M derived: sum of 3 quarters · filed 2024-05-13 | $12.49M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $5.81M derived: sum of 2 quarters · filed 2024-02-29 | $9.75M derived: sum of 3 quarters · filed 2024-02-29 | $12.20M 10-K · filed 2024-02-29 | ||||
| 2022-09-30 | $2.78M 10-Q · filed 2023-11-09 | $2.95M 10-Q · filed 2022-11-07 | $6.72M derived: sum of 2 quarters · filed 2023-11-09 | $9.17M 10-Q · filed 2023-11-09 | $9.83M 10-Q · filed 2022-11-07 | $12.53M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $3.94M 10-Q · filed 2023-08-08 | $4.16M 10-Q · filed 2022-08-11 | $6.39M 10-Q · filed 2023-08-08 | $6.88M 10-Q · filed 2022-08-11 | $9.74M derived: sum of 3 quarters · filed 2023-08-08 | $13.51M derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | $2.44M 10-Q · filed 2023-05-09 | $2.72M 10-Q · filed 2022-05-09 | $5.80M derived: sum of 2 quarters · filed 2023-05-09 | $9.56M derived: sum of 3 quarters · filed 2023-05-09 | $13.01M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $7.12M derived: sum of 2 quarters · filed 2023-03-06 | $10.57M derived: sum of 3 quarters · filed 2023-03-06 | $15.93M 10-K · filed 2023-03-06 | ||||
| 2021-09-30 | $3.76M 10-Q · filed 2022-11-07 | $7.21M derived: sum of 2 quarters · filed 2022-11-07 | $12.57M 10-Q · filed 2022-11-07 | $14.84M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | $3.45M 10-Q · filed 2022-08-11 | $8.81M 10-Q · filed 2022-08-11 | $11.08M derived: sum of 3 quarters · filed 2022-08-11 | $16.07M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $5.36M 10-Q · filed 2022-05-09 | $7.63M derived: sum of 2 quarters · filed 2022-05-09 | $12.62M derived: sum of 3 quarters · filed 2022-05-09 | $16.14M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $7.26M derived: sum of 2 quarters · filed 2022-03-02 | $10.78M derived: sum of 3 quarters · filed 2022-03-02 | $15.67M 10-K · filed 2022-03-02 | ||||
| 2020-09-30 | $4.99M 10-Q · filed 2021-11-12 | $8.51M derived: sum of 2 quarters · filed 2021-11-12 | $13.40M 10-Q · filed 2021-11-12 | $17.37M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $3.52M 10-Q · filed 2021-08-10 | $8.41M 10-Q · filed 2021-08-10 | $12.38M derived: sum of 3 quarters · filed 2021-08-10 | $15.43M derived: sum of 4 quarters · filed 2021-08-10 | ||||
| 2020-03-31 | $4.89M 10-Q · filed 2021-05-07 | $8.86M derived: sum of 2 quarters · filed 2021-05-07 | $11.91M derived: sum of 3 quarters · filed 2021-05-07 | $15.84M derived: sum of 4 quarters · filed 2021-05-07 | ||||
| 2019-12-31 | $3.97M 10-K · filed 2020-03-13 | $7.02M derived: sum of 2 quarters · filed 2020-11-09 | $10.95M derived: sum of 3 quarters · filed 2020-11-09 | $15.44M 10-K · filed 2021-03-17 | ||||
| 2019-09-30 | $3.05M 10-Q · filed 2020-11-09 | $6.98M derived: sum of 2 quarters · filed 2020-11-09 | $11.46M 10-Q · filed 2020-11-09 | $16.38M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | $3.93M 10-Q · filed 2020-08-05 | $8.41M 10-Q · filed 2020-08-05 | $13.33M derived: sum of 3 quarters · filed 2020-08-05 | $16.80M derived: sum of 4 quarters · filed 2020-08-05 | ||||
| 2019-03-31 | $4.49M 10-Q · filed 2020-05-07 | $9.40M derived: sum of 2 quarters · filed 2020-05-07 | $12.87M derived: sum of 3 quarters · filed 2020-05-07 | $16.39M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $4.92M 10-K · filed 2020-03-13 | $8.38M derived: sum of 2 quarters · filed 2020-03-13 | $11.90M derived: sum of 3 quarters · filed 2020-03-13 | $12.83M 10-K · filed 2020-03-13 | ||||
| 2018-09-30 | $3.47M 10-K · filed 2020-03-13 | $3.48M 10-Q · filed 2018-11-07 | $6.98M derived: sum of 2 quarters · filed 2020-03-13 | $7.91M 10-Q · filed 2019-11-06 | $8.02M 10-Q · filed 2018-11-07 | $9.03M derived: sum of 4 quarters · filed 2020-03-13 | ||
| 2018-06-30 | $3.52M 10-K · filed 2020-03-13 | $3.61M 10-Q · filed 2018-08-07 | $4.44M 10-Q · filed 2019-08-07 | $4.54M 10-Q · filed 2018-08-07 | $5.56M derived: sum of 3 quarters · filed 2020-03-13 | $6.68M derived: sum of 4 quarters · filed 2020-03-13 | ||
| 2018-03-31 | $927.00K 10-K · filed 2020-03-13 | $2.04M derived: sum of 2 quarters · filed 2020-03-13 | $3.17M derived: sum of 3 quarters · filed 2020-03-13 | $4.14M derived: sum of 4 quarters · filed 2020-03-13 | ||||
| 2017-12-31 | $1.12M 10-K · filed 2019-03-07 | $2.24M derived: sum of 2 quarters · filed 2019-03-07 | $3.21M derived: sum of 3 quarters · filed 2019-03-07 | $3.73M 10-K · filed 2019-03-07 | ||||
| 2017-09-30 | $1.12M 10-K · filed 2019-03-07 | $2.10M derived: sum of 2 quarters · filed 2019-03-07 | $2.61M 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $977.00K 10-K · filed 2019-03-07 | $1.49M 10-Q · filed 2018-08-07 | ||||||
| 2017-03-31 | $515.00K 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |